Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody-Drug Conjugates

被引:32
作者
Zhang, Donglu [1 ]
Fourie-O'Donohue, Aimee [2 ]
Dragovich, Peter S. [3 ]
Pillow, Thomas H. [3 ]
Sadowsky, Jack D. [4 ]
Kozak, Katherine R. [2 ]
Cass, Robert T. [1 ]
Liu, Liling [1 ]
Deng, Yuzhong [1 ]
Liu, Yichin [2 ]
Hop, Cornelis E. C. A. [1 ]
Khojasteh, S. Cyrus [1 ]
机构
[1] Genentech Inc, Drug Metab & Pharmacokinet, 1 DNA Way MS 412a, San Francisco, CA 94080 USA
[2] Genentech Inc, Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA
[3] Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA
[4] Genentech Inc, Prot Chem, San Francisco, CA 94080 USA
关键词
SITE-SPECIFIC CONJUGATION; ANTICANCER PRODRUGS; THIOREDOXIN; CYSTEINE; GLUTATHIONE; DELIVERY;
D O I
10.1124/dmd.118.086132
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In cells, catalytic disulfide cleavage is an essential mechanism in protein folding and synthesis. However, detailed enzymatic catalytic mechanism relating cleavage of disulfide bonds in xenobiotics is not well understood. This study reports an enzymatic mechanism of cleavage of disulfide bonds in xenobiotic small molecules and antibody conjugate (ADC) linkers. The chemically stable disulfide bonds in substituted disulfide-containing pyrrolobenzodiazepine (PBD, pyrrolo[2,1-c][1,4]benzodiazepine) monomer prodrugs in presence of glutathione or cysteine were found to be unstable in incubations in whole blood of humans and rats. It was shown the enzymes involved were thioredoxin (TRX) and glutaredoxin (GRX). For a diverse set of drug-linker conjugates, we determined that TRX in the presence of TRX-reductase and NADPH generated the cleaved products that are consistent with catalytic disulfide cleavage and linker immolation. GRX was less rigorously studied; in the set of compounds studied, its role in the catalytic cleavage was also confirmed. Collectively, these in vitro experiments demonstrate that TRX as well as GRX can catalyze the cleavage of disulfide bonds in both small molecules and linkers of ADCs.
引用
收藏
页码:1156 / 1163
页数:8
相关论文
共 50 条
  • [41] Dextramabs: A Novel Format of Antibody-Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold
    Schneider, Hendrik
    Deweid, Lukas
    Pirzer, Thomas
    Yanakieva, Desislava
    Englert, Simon
    Becker, Bastian
    Avrutina, Olga
    Kolmar, Harald
    CHEMISTRYOPEN, 2019, 8 (03) : 354 - 357
  • [42] Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site
    Kumar, Amit
    Mao, Shenlan
    Dimasi, Nazzareno
    Gao, Changshou
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 11
  • [43] Antibody-drug conjugates: recent advances in conjugation and linker chemistries
    Tsuchikama, Kyoji
    An, Zhiqiang
    PROTEIN & CELL, 2018, 9 (01) : 33 - 46
  • [44] The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
    Han, Seungmin
    Lim, Kwang Suk
    Blackburn, Brody J.
    Yun, Jina
    Putnam, Charles W.
    Bull, David A.
    Won, Young-Wook
    PHARMACEUTICS, 2022, 14 (08)
  • [45] Clinical strategies with antibody-drug conjugates as potential modifications for virotherapy
    Liao, Zi-Xian
    Huang, Po-Hsiang
    Hsu, Shan-hui
    Chang, Hsiung-Hao
    Chang, Chi-Heng
    Tseng, S. -Ja
    DRUG DISCOVERY TODAY, 2024, 29 (11)
  • [46] Challenges and new frontiers in analytical characterization of antibody-drug conjugates
    Wagh, Anil
    Song, Hangtian
    Zeng, Ming
    Tao, Li
    Das, Tapan K.
    MABS, 2018, 10 (02) : 222 - 243
  • [47] Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates
    Xu, Shi
    PHARMACEUTICAL RESEARCH, 2015, 32 (11) : 3577 - 3583
  • [48] Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates
    Zhang, Donglu
    Yu, Shang-Fan
    Khojasteh, S. Cyrus
    Ma, Yong
    Pillow, Thomas H.
    Sadowsky, Jack D.
    Su, Dian
    Kozak, Katherine R.
    Xu, Keyang
    Polson, Andrew G.
    Dragovich, Peter S.
    Hop, Cornelis E. C. A.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (03) : 677 - 685
  • [49] Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies
    He, Jun
    Zeng, Xianghua
    Wang, Chunmei
    Wang, Enwen
    Li, Yongsheng
    MEDCOMM, 2024, 5 (08):
  • [50] Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates
    Hasan, Md Mahbub
    Laws, Mark
    Jin, Peiqin
    Rahman, Khondaker Miraz
    DRUG DISCOVERY TODAY, 2022, 27 (01) : 354 - 361